Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic Toxicity.
Journal: JCO precision oncology
Published: April 23, 2026
Refining first-line therapy in ALK-positive non-small cell lung cancer: final overall survival from the ALEX trial and an evolving treatment landscape.
Journal: Journal of thoracic disease
Published: April 18, 2026
First Report of Response to Tarlatamab in a Patient With Histologic-Transformed SCLC From ALK-Rearranged NSCLC: Case Report.
Journal: JTO clinical and research reports
Published: January 26, 2026
A multi-institutional perspective on tarlatamab administration and management of CRS/ICANS.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 17, 2025
Multi-Institution Analysis of Tarlatamab for the Treatment of EGFR-Mutant Transformed Small Cell Lung Cancer.
Journal: JCO precision oncology
Published: October 30, 2025
Emergency Department-to-Outpatient Oncology Transitions of Care Through a Cancer Diagnostics Program: Implementation and Feasibility.
Journal: Journal of the American College of Radiology : JACR
Published: September 28, 2025
Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC-A Real-World Case Series: Case Report.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: January 25, 2025
Showing 1-8 of 8
Last Updated: 09/26/2026